| P/E (FY) | 33.7 | Sales (TTM) | $2.44B |
| Earnings (TTM) | $826.3M | ROE | — |
| Net Margin | 32.42% | ROIC | 8.89% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | 161.10% | Sales Growth 3Y | 2.06% |
Royalty Pharma buys biopharmaceutical royalties and funds innovation in the biopharmaceutical industry in the United States. Its portfolio holds royalties on roughly 35 marketed therapies and 20 development-stage candidates across rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company also has an R&D funding collaboration to advance JNJ-4804, an investigational medicine for autoimmune diseases.
| Market Cap | $33.85B | Trading Days | 3186 |
| 52W High | 60.08 |
| 52W Low | 34.08 |
| % Off High | −0.18% |
| YTD | 56.70% | 1Y | 65.29% |
| 3Y | 107.90% | 5Y | 75.03% |
| 10Y | 3704.22% | Since incept. (ann.) | 17.55% |
Financial Royalty Assets 95% · Royalty Income Other 5%
| Ann. Volatility (1Y) | 22.79% | Ann. Volatility (3Y) | 23.41% |
| Sharpe (1Y) | 2.35 | Sharpe (3Y) | 1.18 |
| Max Drawdown (1Y) | −7.38% | Max Drawdown (3Y) | −20.66% |
| Beta (3Y, vs SPY) | 0.58 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| ZTS | Zoetis Inc. | $32.49B | 12.9 |
| TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | $36.88B | 26.2 |
| ALNY | ALNYLAM PHARMACEUTICALS, INC. | $38.25B | 123.8 |
| ROIV | Roivant Sciences Ltd. | $24.34B | — |
| INSM | INSMED Inc | $22.57B | — |
| UTHR | UNITED THERAPEUTICS Corp | $22.23B | 18.8 |
| VTRS | Viatris Inc | $20.80B | — |
| ZLAB | Zai Lab Ltd | $20.39B | — |
| REGN | REGENERON PHARMACEUTICALS, INC. | $65.32B | 16.8 |
| BBIO | BridgeBio Pharma, Inc. | $16.76B | — |
| JAZZ | Jazz Pharmaceuticals plc | $16.12B | — |
| QNRX |
| Quoin Pharmaceuticals, Ltd. |
| $14.09B |
| — |
